A randomised, double-blind phase II study evaluating cediranib vs cediranib and saracatinib in patients with relapsed metastatic clear cell renal cancer (COSAK)
Powles, T., Brown, J., Larkin, J., Jones, R., Ralph, C., Hawkins, R., Chowdhury, S., Boleti, E., Bhal, A., Fife, K., Webb, A., Crabb, S., Geldart, T., Hill, R., Dunlop, J., Hall, P. E., McLaren, D., ALanguage:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw014
Date:
January, 2016
File:
PDF, 588 KB
english, 2016
File converter
More search results
More benefits 
